Actively Recruiting
Phase III Trial Evaluating Vorasidenib Plus Temozolomide After Radiation Therapy in Newly Diagnosed Grade 3 IDH-Mutant Astrocytoma
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
408
Participants Needed
177
Research Sites
343 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating vorasidenib combined with temozolomide compared to temozolomide alone in patients newly diagnosed with grade 3 IDH-mutant astrocytoma after radiation therapy. This phase III trial aims to see if adding vorasidenib improves progression-free survival and overall treatment outcomes. The study also assesses safety, response rates, and quality of life measures in this patient group. Participants receive radiation therapy daily Monday through Friday for 33 sessions using methods like intensity-modulated radiation therapy or proton therapy. Four weeks after radiation, patients start 28-day treatment cycles with temozolomide given orally on days 1 to 5, combined with either vorasidenib or a placebo taken daily for 28 days. This treatment repeats up to 12 months unless disease progression or unacceptable side effects occur. Throughout the study, patients undergo regular MRI scans and blood sample collections. After completing treatment, follow-up occurs every three months for two years, then every four months for another two years, and every six months up to 10 years. Researchers will measure progression-free survival, overall survival, tumor response, time to next treatment, symptom burden, and quality of life over this period.
CONDITIONS
Brief Title
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Research Team
A
Alexandra Alexandra LeVasseur
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here